{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:20:34Z","timestamp":1790814034299,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["R01GM086596"],"award-info":[{"award-number":["R01GM086596"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["LCI699"],"award-info":[{"award-number":["LCI699"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005709","name":"Endocrine Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005709","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM086596"],"award-info":[{"award-number":["R01GM086596"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jsbmb.2023.106316","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T09:31:28Z","timestamp":1682242288000},"page":"106316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450"],"prefix":"10.1016","volume":"231","author":[{"given":"Juan","family":"Valent\u00edn-Goyco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-Ming","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Auchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2023.106316_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2023.106316_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing's disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2023.106316_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.jsbmb.2023.106316_bib4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib6","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2023.106316_bib7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","article-title":"Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy","volume":"31","author":"Schumacher","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.jsbmb.2023.106316_bib8","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jsbmb.2023.106316_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12967-014-0340-9","article-title":"Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects","volume":"12","author":"Menard","year":"2014","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.jsbmb.2023.106316_bib10","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","article-title":"Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of cushing syndrome: an in vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2023.106316_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-22-0208","article-title":"Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients","volume":"187","author":"Bonnet-Serrano","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib12","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1021\/acs.biochem.7b00034","article-title":"Molecular recognition in mitochondrial cytochromes P450 that catalyze the terminal steps of corticosteroid biosynthesis","volume":"56","author":"Peng","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2023.106316_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jsbmb.2018.03.003","article-title":"Catalytic modulation of human cytochromes P450 17A1 and P450 11B2 by phospholipid","volume":"181","author":"Peng","year":"2018","journal-title":"J. Steroid Biochem Mol. Biol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib14","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1021\/acs.biochem.6b00532","article-title":"Cytochrome b5 activates the 17,20-lyase activity of human cytochrome P450 17A1 by increasing the coupling of NADPH consumption to androgen production","volume":"55","author":"Peng","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2023.106316_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/HYPERTENSIONAHA.119.13866","article-title":"Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping","volume":"75","author":"Turcu","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jsbmb.2023.106316_bib16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-19-0905","article-title":"Abiraterone acetate treatment lowers 11-oxygenated androgens","volume":"182","author":"Wright","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib17","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1210\/en.2005-1141","article-title":"Arginine 276 controls the directional preference of AKR1C9 (rat liver 3\u03b1-hydroxysteroid dehydrogenase) in human embryonic kidney 293 cells","volume":"147","author":"Papari-Zareei","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2023.106316_bib18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1074\/jbc.RA118.006214","article-title":"Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design","volume":"294","author":"Brixius-Anderko","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2023.106316_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/abbi.1998.0621","article-title":"Expression of catalytically active human cytochrome P450scc in Escherichia coli and mutagenesis of isoleucine-462","volume":"353","author":"Woods","year":"1998","journal-title":"Arch. Biochem Biophys."},{"key":"10.1016\/j.jsbmb.2023.106316_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/js.2018-00130","article-title":"Predicted benign and synonymous variants in CYP11A1 cause primary adrenal insufficiency through missplicing","volume":"3","author":"Maharaj","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.jsbmb.2023.106316_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-62703-321-3_10","article-title":"Nanodiscs in the studies of membrane-bound cytochrome P450 enzymes","volume":"987","author":"Luthra","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib22","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1124\/dmd.111.040071","article-title":"Production of 22-hydroxy metabolites of vitamin D3 by cytochrome P450scc (CYP11A1) and analysis of their biological activities on skin cells","volume":"39","author":"Tuckey","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jsbmb.2023.106316_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0005-2744(69)90420-3","article-title":"Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors","volume":"185","author":"Morrison","year":"1969","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.jsbmb.2023.106316_bib24","first-page":"5488","article-title":"Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis","volume":"50","author":"Gazdar","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.jsbmb.2023.106316_bib25","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2023.106316_bib26","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1016\/0303-7207(93)90175-J","article-title":"Angiotensin increases aldosterone synthase mRNA levels in human NCI-H295 cells","volume":"94","author":"Holland","year":"1993","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsbmb.2017.12.002","article-title":"Functional characterization of the G162R and D216H genetic variants of human CYP17A1","volume":"178","author":"Capper","year":"2018","journal-title":"J. Steroid Biochem Mol. Biol."},{"key":"10.1016\/j.jsbmb.2023.106316_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2020.111120","article-title":"Conformational selection is present in ligand binding to cytochrome P450 19A1 lipoprotein nanodiscs","volume":"209","author":"Zarate-Perez","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.jsbmb.2023.106316_bib29","doi-asserted-by":"crossref","first-page":"15746","DOI":"10.1021\/ja805772r","article-title":"Allosteric effects on substrate dissociation from cytochrome P450 3A4 in nanodiscs observed by ensemble and single-molecule fluorescence spectroscopy","volume":"130","author":"Nath","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jsbmb.2023.106316_bib30","doi-asserted-by":"crossref","first-page":"12975","DOI":"10.1074\/jbc.RA119.009830","article-title":"Human cytochrome P450 11B2 produces aldosterone by a processive mechanism due to the lactol form of the intermediate 18-hydroxycorticosterone","volume":"294","author":"Reddish","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2023.106316_bib31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2023.106316_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2022.111934","article-title":"Redox partner adrenodoxin alters cytochrome P450 11B1 ligand binding and inhibition","volume":"235","author":"Loomis","year":"2022","journal-title":"J. Inorg. Biochem."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076023000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076023000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:54:28Z","timestamp":1778568868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076023000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":32,"alternative-id":["S0960076023000717"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2023.106316","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2023.106316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106316"}}